Key Takeaways
- • Amulet Capital Partners, a middle-market healthcare-focused private equity firm, promoted Sam Brinkley to Partner, recognizing his six-year tenure and leadership across the firm's fertility and reproductive health investment portfolio.
- • Brinkley's career progression at Amulet spans Vice President (2020), Principal (2024), and Partner (2026), demonstrating consistent advancement within the firm's investment hierarchy.
- • Brinkley has played a central role in major fertility and reproductive health investments, including US Fertility, Genetics & IVF Institute, and TFP Fertility Group, areas where Amulet maintains deep sector expertise and identifies continued opportunity.
- • Amulet's leadership emphasized Brinkley's partnership mindset, disciplined execution capability, and strategic focus on clinical excellence, physician alignment, and operational execution as core to the firm's healthcare investment philosophy.
- • The promotion reflects Amulet's ongoing expansion and deepening commitment to fertility and reproductive health as a differentiated investment thesis within its healthcare portfolio.
Summary
Amulet Capital Partners, a middle-market private equity firm exclusively focused on healthcare investments, announced the promotion of Sam Brinkley to Partner on September 18, 2026. The elevation recognizes Brinkley's six-year tenure at the firm and his instrumental contributions to Amulet's fertility and reproductive health investment strategy.
Brinkley joined Amulet in 2020 as a Vice President, advanced to Principal in 2024, and now assumes Partner status. According to Ramsey Frank, CEO of Amulet, Brinkley has demonstrated "partnership mindset, disciplined execution, and deep understanding of healthcare businesses" that align with the firm's investment approach and value creation methodology. Jay Rose, President of Amulet, specifically highlighted Brinkley's involvement in the firm's fertility sector investments, noting his ability to "navigate complex situations and worked closely with management teams to build and scale businesses grounded in clinical excellence, physician alignment, and operational execution."
Throughout his tenure, Brinkley has been instrumental in executing and managing several major fertility-focused portfolio companies, including US Fertility, Genetics & IVF Institute, and TFP Fertility Group. He has also supported Amulet's broader strategic initiatives across the investment lifecycle, from deal sourcing and evaluation through transaction execution and long-term portfolio management alongside management teams. Prior to joining Amulet, Brinkley was an Investment Associate at The Riverside Company, a middle-market private equity firm.
The promotion underscores Amulet's conviction in fertility and reproductive health as a compelling investment opportunity within healthcare. The firm has demonstrated sustained focus on this sector and continues to identify meaningful value creation potential in businesses that combine clinical excellence with operational rigor and physician-aligned incentive structures.
Brinkley joined Amulet in 2020 as a Vice President, advanced to Principal in 2024, and now assumes Partner status. According to Ramsey Frank, CEO of Amulet, Brinkley has demonstrated "partnership mindset, disciplined execution, and deep understanding of healthcare businesses" that align with the firm's investment approach and value creation methodology. Jay Rose, President of Amulet, specifically highlighted Brinkley's involvement in the firm's fertility sector investments, noting his ability to "navigate complex situations and worked closely with management teams to build and scale businesses grounded in clinical excellence, physician alignment, and operational execution."
Throughout his tenure, Brinkley has been instrumental in executing and managing several major fertility-focused portfolio companies, including US Fertility, Genetics & IVF Institute, and TFP Fertility Group. He has also supported Amulet's broader strategic initiatives across the investment lifecycle, from deal sourcing and evaluation through transaction execution and long-term portfolio management alongside management teams. Prior to joining Amulet, Brinkley was an Investment Associate at The Riverside Company, a middle-market private equity firm.
The promotion underscores Amulet's conviction in fertility and reproductive health as a compelling investment opportunity within healthcare. The firm has demonstrated sustained focus on this sector and continues to identify meaningful value creation potential in businesses that combine clinical excellence with operational rigor and physician-aligned incentive structures.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.